Ken Griffin Veracyte, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$21.0 - $35.25 $321,300 - $539,325	-15,300 Reduced 65.95%	7,900 $268,000
Q2 2024 Aug 14, 2024	BUY	$18.86 - $23.55 $273,470 - $341,475	14,500 Added 166.67%	23,200 $502,000
Q1 2024 May 15, 2024	BUY	$21.0 - $29.1 $33,600 - $46,560	1,600 Added 22.54%	8,700 $192,000
Q4 2023 Feb 14, 2024	BUY	$19.72 - $28.68 $49,300 - $71,700	2,500 Added 54.35%	7,100 $195,000
Q3 2023 Nov 14, 2023	SELL	$22.33 - $29.92 $91,553 - $122,672	-4,100 Reduced 47.13%	4,600 $102,000
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $165,584 - $213,221	-7,900 Reduced 47.59%	8,700 $221,000
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $51,449 - $69,725	2,500 Added 17.73%	16,600 $370,000
Q4 2022 Feb 14, 2023	SELL	$15.31 - $29.94 $2.01 Million - $3.92 Million	-131,000 Reduced 90.28%	14,100 $334,000
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $1,657 - $2,790	100 Added 0.07%	145,100 $2.41 Million

308

81.8M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.13B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.